Dataset Information

CK1δ/CK1ε Signaling is Necessary to Sustain mitochondrial Metabolism and Cell Survival in Multiple Myeloma

ABSTRACT: Multiple myeloma (MM) remains an incurable malignancy due to the acquisition of intrinsic programs that drive therapy resistance. Here we report that casein kinase-1δ (CK1δ) and CK1ε are therapeutic targets for MM that control mitochondrial metabolism. Specifically, SR-3029, a dual CK1δ/CK1ε inhibitor, has potent anti-MM activity in vivo and ex vivo (in 74/75 patient specimens). Mechanistically, RNA sequencing (RNA-seq) and metabolic analyses revealed that inhibiting CK1δ/CK1ε disables MM metabolism, by suppressing genes involved in oxidative phosphorylation (OxPhos), reducing citric acid cycle intermediates, and suppressing Complexes I and IV of the electron transport chain. Finally, sensitivity of MM patient specimens to SR-3029 correlates with elevated expression of mitochondrial genes, and RNA-seq of tumor cells from 687 MM patients spanning the spectrum from newly diagnosed to late relapsed refractory disease revealed increased CSNK1D, CSNK1E, and OxPhos genes correlate with disease progression and inferior outcomes. Thus, increases in mitochondrial metabolism are a hallmark of MM progression that can be disabled by targeting CK1δ/CK1ε.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): B Cell

DISEASE(S): Multiple Myeloma

SUBMITTER: John Koomen

LAB HEAD: Kenneth Shain, MD/PhD

PROVIDER: PXD025808 | Pride | 2024-01-26

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 201

Publications

CK1δ and CK1ε Signaling Sustains Mitochondrial Metabolism and Cell Survival in Multiple Myeloma.

Burger Karen L KL Fernandez Mario R MR Meads Mark B MB Sudalagunta Praneeth P Oliveira Paula S PS Renatino Canevarolo Rafael R Alugubelli Raghunandan Reddy RR Tungsevik Alexandre A De Avila Gabe G Silva Maria M Graeter Allison I AI Dai Hongyue A HA Vincelette Nicole D ND Prabhu Antony A Magaletti Dario D Yang Chunying C Li Weimin W Kulkarni Amit A Hampton Oliver O Koomen John M JM Roush William R WR Monastyrskyi Andrii A Berglund Anders E AE Silva Ariosto S AS Cleveland John L JL Shain Kenneth H KH

Cancer research 20231201 23

Multiple myeloma remains an incurable malignancy due to acquisition of intrinsic programs that drive therapy resistance. Here we report that casein kinase-1δ (CK1δ) and CK1ε are therapeutic targets in multiple myeloma that are necessary to sustain mitochondrial metabolism. Specifically, the dual CK1δ/CK1ε inhibitor SR-3029 had potent in vivo and ex vivo anti-multiple myeloma activity, including against primary multiple myeloma patient specimens. RNA sequencing (RNA-seq) and metabolic analyses re ...[more]

PMID: 37702657

Similar Datasets

Project description:Natural Killer cells (NK), a major constituent of innate immune system, have the ability to kill the transformed and infected cells without prior sensitization; can be put to immunotherapeutic use against various malignancies. NK cells discriminate between normal cells and transformed cells via a balance of inhibitory and activating signals induced by interactions between NK cell receptors and target cell ligands. Present study investigates whether expansion of NK cells could augment their anti-myeloma (MM) activity. For NK cell expansion, peripheral blood mononuclear cells from healthy donors and myeloma patients were co-cultured with irradiated K562 cells transfected with 4-1BBL and membrane-bound IL15 (K562-mb15-41BBL). A genome-wide profiling approach was performed to identify gene expression signature in expanded NK (ENK) cells and non-expanded NK cells isolated from healthy donors and myeloma patients. A specific set of genes involved in proliferation, migration, adhesion, cytotoxicity, and activation were up regulated post expansion, also confirmed by flow cytometry. Exp-NK cells killed both allogeneic and autologous primary MM cells more avidly than non-exp-NK cells in vitro. Multiple receptors, particularly NKG2D, natural cytotoxicity receptors, and DNAM-1 contributed to target lysis, via a perforin mediated mechanism. In summary, vigorous expansion and high anti-MM activity both in vitro and in vivo provide the rationale for testing exp-NK cells in a clinical trial for high risk MM. Differential gene expression profile in expanded natural killer (ENK) cells and non-expanded natural killer (NK) cells from healthy donors and myeloma patients Eight healthy donor and eight myeloma patients were used in the study. Non-expanded natural killer (NK) cells were isolated from PBMCs of healthy donors and myeloma patients. Expanded natural killer (ENK) cells were generated from same set of samples as mentioned in expansion protocol. All ENK and NK cells were used for gene expression profiling.

			Action	DRS
	F009417.dat	Other
	F009418.dat	Other
	F009419.dat	Other
	F009420.dat	Other
	F009421.dat	Other